| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
CELC
Celcuity
|
Jun 02, 2026 | BUY |
Strong Buy
+40.6% avg upside
16 analysts
|
$165.00
87.93% Upside
|
-3.7% |
|
CRBP
Corbus Pharmaceuticals
|
May 26, 2026 | BUY |
Strong Buy
+338.6% avg upside
20 analysts
|
$38.00
360.09% Upside
|
· |
|
CADL
Candel Therapeutics
|
May 16, 2026 | BUY |
Strong Buy
+112.6% avg upside
10 analysts
|
$16.00
92.47% Upside
|
+10.4% |
|
INBX
Inhibrx Biosciences Inc
|
May 16, 2026 | BUY |
Strong Buy
+198.3% avg upside
5 analysts
|
$230.00
147.22% Upside
|
-12.8% |
|
AURA
Aura Biosciences Inc
|
May 16, 2026 | BUY |
Strong Buy
+234.5% avg upside
9 analysts
|
$23.00
262.81% Upside
|
-14.2% |
|
CATX
Perspective Therapeutics
|
May 16, 2026 | BUY |
Strong Buy
+278.9% avg upside
22 analysts
|
$15.00
408.42% Upside
|
-22.1% |
|
JANX
Janux Therapeutics Inc
|
May 09, 2026 | BUY |
Strong Buy
+217.9% avg upside
21 analysts
|
$60.00
321.92% Upside
|
-0.6% |
|
GLUE
Monte Rosa Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+27.3% avg upside
14 analysts
|
— | -7.6% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.